Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
|Author/s||López Cortés, Luis Fernando
Viciana Fernández, Pompeyo
Martínez-Pérez, Maria A.
Mohamed-Balghata, Mohamed O.
|Department||Universidad de Sevilla. Departamento de Medicina|
|Abstract||Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen
for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide ...
Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to ,50 copies/mL after 24 weeks on treatment, or a confirmed viral load .200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9–92.1%) and 77.4% (CI95, 65.0–89.7%), respectively; the rates reached 97.2% (CI95, 95.1–99.3%) and 90.5% (CI95, 81.7–99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1–2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity.
|Citation||López Cortés, L.F., Viciana Fernández, P., Girón-González, J., Romero-Palacios, A., Márquez-Solero, M., Martínez-Pérez, M.A. y Mohamed-Balghata, M.O. (2014). Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE, 9 (5), art. n. 97262.|
|Clinical and Virological Effic ...||1007.Kb||[PDF]||View/||Clinical and Virological Efficacy|